⌘K
Loading ticker…
As of 2026-08-24, Pfizer Inc. (PFE) has a 3-month relative strength percentile of 63 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.1%, relative volume 0.58×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PFE is in a stage 1 base, week 12. Currently in a 99-day base; basing ADR 1.9% (broad 2.2%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 10.1% / 7.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
PFE appears in 1 ETF as of Jun 2026: WBIY at 4.17% weight, $2M notional.
Held by 315 ETFs · $23.7B across latest filings · largest weight 7.56% (OZEM).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| WBIY | 4.17% | $2M | −0.70 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PFE Jan avg: -3.40% median: -2.99% win: 25% σ: 8.53% n: 4 2022-04-12 → 2026-07-31 | PFE Feb avg: -1.45% median: -1.13% win: 25% σ: 5.24% n: 4 2022-04-12 → 2026-07-31 | PFE Mar avg: 0.62% median: 1.06% win: 75% σ: 3.57% n: 4 2022-04-12 → 2026-07-31 | PFE Apr avg: -5.99% median: -4.92% win: 0% σ: 2.25% n: 5 2022-04-12 → 2026-07-31 | PFE May avg: 2.40% median: -1.95% win: 40% σ: 7.08% n: 5 2022-04-12 → 2026-07-31 | PFE Jun avg: -2.38% median: -2.37% win: 20% σ: 4.05% n: 5 2022-04-12 → 2026-07-31 | PFE Jul avg: 0.75% median: -1.69% win: 40% σ: 5.64% n: 5 2022-04-12 → 2026-07-31 | PFE Aug avg: -2.76% median: -3.45% win: 25% σ: 7.01% n: 4 2022-04-12 → 2026-07-31 (current) | PFE Sep avg: -1.71% median: -1.75% win: 25% σ: 3.93% n: 4 2022-04-12 → 2026-07-31 | PFE Oct avg: -1.74% median: -2.73% win: 25% σ: 5.94% n: 4 2022-04-12 → 2026-07-31 | PFE Nov avg: 1.11% median: 2.06% win: 50% σ: 6.54% n: 4 2022-04-12 → 2026-07-31 | PFE Dec avg: -1.33% median: -1.02% win: 50% σ: 3.67% n: 4 2022-04-12 → 2026-07-31 |